CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

被引：124

作者：

Maisey, NR ^{[1
]}

Norman, AR ^{[1
]}

Hill, A ^{[1
]}

Massey, A ^{[1
]}

Oates, J ^{[1
]}

Cunningham, D ^{[1
]}

机构：

[1] Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England

来源：

BRITISH JOURNAL OF CANCER | 2005年 / 93卷 / 07期

关键词：

pancreatic cancer; CA19-9; prognosis; chemotherapy;

D O I：

10.1038/sj.bjc.6602760

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In a multivariate analysis of 154 patients receiving chemotherapy, baseline CA19-9 was an independent prognostic factor for overall survival (OS) (HR 1.8; 95% CI: 1.3 - 2.5, P = 0.0004). The 1-year OS was 19 and 46%, respectively, for patients with a baseline CA19-9 above or below the median value. A fall of 20% in CA19-9 level from baseline was an independent prognostic factor for OS ( HR 1.9; 95% CI: 1.1 - 3.4, P = 0.019).

引用

页码：740 / 743

页数：4

共 50 条

[41] A COMPARISON OF CA-195 WITH CA19-9 IN PATIENTS WITH PANCREATIC-CANCER
DEMERS, LM
GLENN, JD
STEINBERG, W
CLINICAL CHEMISTRY, 1988, 34 (06) : 1294 - 1294
[42] Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma
Nurmi, Anna M.
Mustonen, Harri K.
Stenman, Ulf-Hakan
Seppanen, Hanna E.
Haglund, Caj H.
SCIENTIFIC REPORTS, 2021, 11 (01)
[43] Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma
Anna M. Nurmi
Harri K. Mustonen
Ulf-Håkan Stenman
Hanna E. Seppänen
Caj H. Haglund
Scientific Reports, 11
[44] Prognostic value of serum CEA and CA19-9 levels in pancreatic ductal adenocarcinoma
Ermiah, Eramah
Eddfair, Mona
Abdulrahman, Othman
Elfagieh, Mohamed
Jebriel, Abdalla
Al-Sharif, Mona
Assidi, Mourad
Buhmeida, Abdelbaset
MOLECULAR AND CLINICAL ONCOLOGY, 2022, 17 (02)
[45] Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis
Mattiucci, Gian Carlo
Morganti, Alessio G.
Cellini, Francesco
Buwenge, Milly
Casadei, Riccardo
Farioli, Andrea
Alfieri, Sergio
Arcelli, Alessandra
Bertini, Federica
Calvo, Felipe A.
Cammelli, Silvia
Fuccio, Lorenzo
Giaccherini, Lucia
Guido, Alessandra
Herman, Joseph M.
Macchia, Gabriella
Maidment, Bert W., III
Miller, Robert C.
Minni, Francesco
Regine, William F.
Reni, Michele
Partelli, Stefano
Falconi, Massimo
Valentini, Vincenzo
TRANSLATIONAL ONCOLOGY, 2019, 12 (01): : 1 - 7
[46] Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels
Ono, Yoshihiro
Inoue, Yosuke
Ito, Hiromichi
Sasaki, Takashi
Takeda, Tsuyoshi
Ozaka, Masato
Sasahira, Naoki
Hiratsuka, Makiko
Matsueda, Kiyoshi
Oba, Atsushi
Sato, Takafumi
Saiura, Akio
Takahashi, Yu
HPB, 2023, 25 (01) : 100 - 108
[47] Duration of Reduced CA19-9 Levels Is a Better Prognostic Factor Than Its Rate of Reduction for Unresectable Locally Advanced Pancreatic Cancer
Tomishima, Ko
Ishii, Shigeto
Fujisawa, Toshio
Ikemura, Muneo
Ota, Hiroto
Kabemura, Daishi
Ushio, Mako
Fukuma, Taito
Takahashi, Sho
Yamagata, Wataru
Takasaki, Yusuke
Suzuki, Akinori
Ito, Koichi
Saito, Hiroaki
Nagahara, Akihito
Isayama, Hiroyuki
CANCERS, 2021, 13 (16)
[48] CA19-9:: A pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin
Heinemann, V
Schermuly, MM
Stieber, P
Schulz, L
Jüngst, D
Wilkowski, R
Schalhorn, A
ANTICANCER RESEARCH, 1999, 19 (4A) : 2433 - 2435
[49] EVALUATION OF A SEROLOGIC MARKER, CA19-9, IN THE DIAGNOSIS OF PANCREATIC-CANCER
PLESKOW, DK
BERGER, HJ
GYVES, J
ALLEN, E
MCLEAN, A
PODOLSKY, DK
ANNALS OF INTERNAL MEDICINE, 1989, 110 (09) : 704 - 709
[50] CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort
Marta Herreros-Villanueva
Lourdes Ruiz-Rebollo
Mario Montes
Mario Rodriguez-Lopez
María Francisco
Joaquín Cubiella
Eduardo Iyo
Emilio Garabitos
Emma Martínez Moneo
Maider Martos
Enrique de Madaria
Ibon Martínez-Arránz
Marta García-Cougil
Agueda Iglesias-Gómez
Luis Bujanda
Molecular Biology Reports, 2020, 47 : 1583 - 1588

← 1 2 3 4 5 →